Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Bacterium or component thereof or substance produced by said...
Reexamination Certificate
2007-11-27
2007-11-27
Swartz, Rodney P (Department: 1645)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Bacterium or component thereof or substance produced by said...
C424S009100, C424S009200, C424S184100, C424S185100, C424S192100, C424S200100, C424S234100, C435S320100, C530S300000, C530S350000, C536S023700
Reexamination Certificate
active
10695155
ABSTRACT:
Vaccines based on one or more combinations of majorly abundant extracellular products of pathogens and methods for their use and production are presented. The most prevalent or majorly abundant extracellular products of a target pathogen are selected irrespective of their absolute molecular immunogenicity and used as vaccines to stimulate a protective immune response in mammalian hosts against subsequent infection by the target pathogen. The majorly abundant extracellular products may be characterized and distinguished by their respective N-terminal amino acid, amino acid, or DNA sequences. As the vaccines may comprise different combinations of the extracellular products, subunits thereof, or encoding nucleic acids, a broad range of effective immunotherapeutic compositions are provided by the present invention. In addition to other infectious agents, the vaccines so produced can be used to stimulate an effective immune response against intracellular pathogens and in particularMycobacterium tuberculosis.
REFERENCES:
patent: 3888837 (1975-06-01), Tsumita et al.
patent: 3943119 (1976-03-01), Tsumita et al.
patent: 4123427 (1978-10-01), Dniel
patent: 4285931 (1981-08-01), Limjuco et al.
patent: 4460503 (1984-07-01), Savrda et al.
patent: 4724144 (1988-02-01), Rook et al.
patent: 4777130 (1988-10-01), Maes
patent: 4889800 (1989-12-01), Shinnick et al.
patent: 4906742 (1990-03-01), Young et al.
patent: 4952395 (1990-08-01), Shinnick et al.
patent: 4965192 (1990-10-01), Maes
patent: 4976958 (1990-12-01), Shinnick et al.
patent: 5108745 (1992-04-01), Horwitz
patent: 5154923 (1992-10-01), Van Eden et al.
patent: 5169940 (1992-12-01), Patarroyo
patent: 5171839 (1992-12-01), Patarroyo
patent: 5225324 (1993-07-01), McFadden et al.
patent: 5254459 (1993-10-01), Patarroyo
patent: 5268170 (1993-12-01), Van Eden et al.
patent: 6471967 (2002-10-01), Horwitz et al.
patent: 6752993 (2004-06-01), Horwitz
patent: 0499003 (1992-08-01), None
patent: 2239246 (1991-06-01), None
patent: WO 85/03639 (1985-08-01), None
patent: WO 88/02027 (1988-03-01), None
patent: WO 88/05823 (1988-08-01), None
patent: WO 88/06626 (1988-09-01), None
patent: WO 89/05825 (1989-06-01), None
patent: WO 89/12455 (1989-12-01), None
patent: WO 90/00594 (1990-01-01), None
patent: WO 90/02564 (1990-03-01), None
patent: WO 90/10449 (1990-09-01), None
patent: WO 90/15873 (1990-12-01), None
patent: WO 91/04272 (1991-04-01), None
patent: WO 91/14448 (1991-10-01), None
patent: WO 92/01783 (1992-02-01), None
patent: WO 92/01796 (1992-02-01), None
patent: WO 92/04462 (1992-03-01), None
patent: WO 92/16628 (1992-10-01), None
patent: WO 92/21376 (1992-12-01), None
patent: WO 92/21697 (1992-12-01), None
patent: WO 92/22326 (1992-12-01), None
patent: WO 93/07897 (1993-04-01), None
patent: WO 93/14118 (1993-07-01), None
patent: WO 93/14789 (1993-08-01), None
patent: WO 94/02508 (1994-02-01), None
patent: WO 95/01440 (1995-01-01), None
patent: WO 95/01441 (1995-01-01), None
patent: WO 95/14713 (1995-06-01), None
C. Abou-Zeid et al., “The Secreted Antigens ofMycobacterium tuberculosis. . . Available Antibodies,” 1988, 134:531-538, J. Gen. Micro.
C. Abou-zeid et al., “Characterization of Fibronectin . . .Mycobacterium bovisBCG,” Dec. 1988, 56(12):3046-3051, Infection and Immunity.
C. Abou-zeid et al., “Genetic and Immunological Analysis . . . Fibronectin-Binding Proteins,” Aug. 1991, 59(8):2712-2718, Infection and Immunity.
E. Adams et al., “T cell reactivity . . . household contacts,” 1990, 80:206-212, Clin. Exp. Immunol.
Allison, A.C. and N.E. Byars, “An adjuvant formulation that selectively elicits the formation of antibodies of protective isotypes and of cell-mediated immunity,” J. Immunol. Meth. 95:157-68, 1986.
Andersen, P., and I Heron. “Specificity of a Protective Memory Immune Response againstMycobacterium tuberculosis.” Infection and Immunology 61 (1993) 844-51.
Belisle, J. T., et al. “Indentification of a Mycolyltransferase fromMycobacterium tuberculosisand the Coincident Definition of the Physiological Function of Antigen 85B.” In the program from the Thirtieth U.S.-Japan Tuberculosis Research Conference, Leprosy Research Conference and Tuberculosis/Leprosy Symposium. U.S.-Japan Cooperative Medical Science Program. Ft. Collins, Colorado (Jul. 19-21, 1995) 212-6.
Berdal, Bjorn P., et al. “Demonstration of Extracellular Chymotrypsin-Like Activity from Various Legionella Species.” Journal of Clinical Microbiology 16 (Sep. 1982) 452-7.
V. Bhardwaj & M.J. Colston, “The processiong and presentation of mycobacterial . . . monocytes,” 1988, 18:691-696, Eur. J. Immunol.
S.J. Blander & M.A. Horwitz, “Vaccination with the Major Secretory Protein . . . Legionnaires' Disease,” Mar. 1989, 169:691-705, J. Exp. Med.
Blander, Steven J., et al. “A Live Avirulent MutantLegionella pneumophilaVaccine Induces Protective Immunity against Lethal Aerosol Challenge.” J. Clin. Invest. 83 (Mar. 1989) 810-5.
Blander, Steven J., et al. “An Immunoprotective Molecule, the Major Secretory Protein ofLegionella pneumophila, Is Not a Virulence Factor in a Guinea Pig Model of Legionnaires' Disease.” Journal of Clinical Investigation 86 (Sep. 1990) 817-24.
Blander, Steven J., and Marcus A. Horwitz. “Vaccination withLegionella pneumophilaMembranes Induces Cell-mediated and Protective Immunity in a Guinea Pig Model of Legionnaries' Disease.” Journal of Clinical Investigation 87 (Mar. 1991 1054-9.
Blander, Steven J., and Marcus A. Horwitz. “Vaccination with the Major Secretory Protein of Legionella Induces Humoral and Cell-mediated Immune Responses and Protective Immunity across Different Serogroups ofLegionella pneumophilaand Different Species of Legionella.” Journal of Immunology 147 (Jul. 1991) 285-91.
Blander, Steven J., and Marcus A. Hortwitz. “Major Cytoplasmic Membrane Protein ofLegionella pneumophila, a Genus Common Antigen and Member of the hsp 60 Family of Heat Shock Proteins, Induces Protective Immunity in a Guinea Pig Model of Legionnaries' Disease.” Journal of Clinical Investigation 91 (Feb. 1993) 717-23.
Bloch, Hubert, and William Segal. “Viability and Multiplication of Vaccines in Immunization Against Tuberculosis.” American Review of Tuberculosis 7(1955) 228-48.
B.R. Bloom et al., “Genes for the protein antigens of the tuberculosis and leprosy bacilli,” 1985, 5:839-845, Science Reports.
Bloom, Barry R. “New Approaches to Vaccine Development.” Reviews of Infectious Disease, 1989, 11(2): S460-6.
Borremans et al., “Cloning, sequence determination, and expression of 32-kilodalton-protein gene ofMycobacterium tuberculosis,” Infect. Immun. 57(10):3123-30, 1989.
Brennan, Patrick J. “Structural of Mycobacteria: Recent Developments in Defining Cell Wall Carbohydrates and Proteins.” Reviews of Infectious Disease, 1989, 11(2): S420-30.
R.F. Breiman & M.A. Horwitz, “Guinea Pigs Sublethally Infected . . . Challenge,” Mar. 1987, 164:799-811, J. Exp. Med.
W.J. Britton et al., “Immunoreactivity of a 70 kD Protein . . . Chromatography,” Sep. 1986, 691-708, J.Ex.Medicine.
K.M. Citron, “Control and prevention of tuberculosis in Britain,” 1988, 44(3):704-716, Br. Med. Bull.
Chen, E. Y., and P. H. Seeburg. “Supercoli Sequencing: A Fast and Simple Method for Sequencing Plasmid DNA.” DNA 4 (1985) 165-70.
Collins, et al., “Biological activity of protein antigens isolated fromMycobacterium tuberculosisculture filtrate,” Infect. Immun. 1988, vol. 56(5), 1260-1266.
Clemens, D. L., and M. A. Horwitz. “Characterization of theMycobacterium tuberculosisPhagosome and Evidence That Phagosmal Is Inhibited.” Journal of Experimental Medicine 181 (1995) 257-70.
G.W. Comstock, “Identification of an Effective Vaccine Against Tuberculosis,” 1988, 138:479-480, Am. Rev. Respir. Dis.
J. Content et al., “T
Harth Günter
Horwitz Marcus A.
Lee Bai-Yu
Cullman Louis C.
Glasky Michelle S.
Kirkpatrick & Lockhart Preston Gates & Ellis LLP
Swartz Rodney P
The Regents of the University of California
LandOfFree
Abundant extracellular products and methods for their... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Abundant extracellular products and methods for their..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Abundant extracellular products and methods for their... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3809581